hydralazine has been researched along with Benign Neoplasms in 16 studies
Hydralazine: A direct-acting vasodilator that is used as an antihypertensive agent.
hydralazine : The 1-hydrazino derivative of phthalazine; a direct-acting vasodilator that is used as an antihypertensive agent.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Among 85 cancer patients that received either 182 mg or 83 mg of hydralazine daily, according to their acetylator status, the mean concentrations of hydralazine in plasma were 239." | 2.76 | Pharmacokinetics of hydralazine, an antihypertensive and DNA-demethylating agent, using controlled-release formulations designed for use in dosing schedules based on the acetylator phenotype. ( Chávez-Blanco, A; de la Cruz-Hernández, E; Duenas-González, A; Fernandez, Z; Gonzalez-Fierro, A; Gutiérrez, O; Pérez-Cardenas, E; Rodriguez, D; Taja-Chayeb, L; Trejo-Becerril, C; Vasquez-Bahena, D; Vidal, S, 2011) |
| " Hydralazine-valproate is safe when used alone or in combination with chemotherapy or chemoradiation." | 2.50 | Hydralazine-valproate: a repositioned drug combination for the epigenetic therapy of cancer. ( Cetina, L; Chavez-Blanco, A; Coronel, J; Dueñas-Gonzalez, A; González-Fierro, A; Taja-Chayeb, L, 2014) |
| "Prostate, colon, breast and cervical cancer cell lines were analyzed for the expression of MICA and MICB at the mRNA and protein levels by RT-PCR, Western blot, flow cytometry and ELISA." | 1.37 | Upregulation of NKG2D ligands and enhanced natural killer cell cytotoxicity by hydralazine and valproate. ( Alatorre, B; Chacón-Salinas, R; Chávez-Blanco, A; Contreras-Paredes, A; De la Cruz-Hernández, E; Domínguez, GI; Dueñas-González, A; Pérez-Cárdenas, E; Rodríguez-Cortez, O; Taja-Chayeb, L; Trejo-Becerril, C; Trujillo, JE, 2011) |
| "In KHT tumors, perfused vessel numbers decreased significantly at 30 min post-hydralazine, then recovered somewhat by 60 min." | 1.31 | Influence of hydralazine administration on oxygenation in spontaneous and transplanted tumor models. ( Fenton, BM, 2001) |
| "The choice of an effective method to treat priapism is challenging because precise causes in the majority of patients have not been well defined." | 1.26 | Priapism: evolution of management in 48 patients in a 22-year series. ( Nelson, JH; Winter, CC, 1977) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (37.50) | 18.7374 |
| 1990's | 1 (6.25) | 18.2507 |
| 2000's | 3 (18.75) | 29.6817 |
| 2010's | 5 (31.25) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Zhou, S | 1 |
| Shang, Q | 1 |
| Ji, J | 1 |
| Luan, Y | 1 |
| Dueñas-Gonzalez, A | 4 |
| Coronel, J | 1 |
| Cetina, L | 2 |
| González-Fierro, A | 3 |
| Chavez-Blanco, A | 4 |
| Taja-Chayeb, L | 4 |
| Linnekamp, JF | 1 |
| Butter, R | 1 |
| Spijker, R | 1 |
| Medema, JP | 1 |
| van Laarhoven, HWM | 1 |
| Vasquez-Bahena, D | 1 |
| Vidal, S | 1 |
| Trejo-Becerril, C | 3 |
| Pérez-Cardenas, E | 3 |
| de la Cruz-Hernández, E | 3 |
| Gutiérrez, O | 1 |
| Rodriguez, D | 1 |
| Fernandez, Z | 1 |
| Domínguez, GI | 1 |
| Rodríguez-Cortez, O | 1 |
| Alatorre, B | 1 |
| Chacón-Salinas, R | 1 |
| Trujillo, JE | 1 |
| Contreras-Paredes, A | 1 |
| Manley, E | 1 |
| Waxman, DJ | 1 |
| SEGURA, FI | 1 |
| PERRY, HM | 1 |
| Nöth, U | 1 |
| Rodrigues, LM | 1 |
| Robinson, SP | 1 |
| Jork, A | 1 |
| Zimmermann, U | 1 |
| Newell, B | 1 |
| Griffiths, JR | 1 |
| Candelaria, M | 1 |
| Gallardo-Rincón, D | 1 |
| Arce, C | 1 |
| Aguilar-Ponce, JL | 1 |
| Arrieta, O | 1 |
| Camargo, MF | 1 |
| Pérez-Plasencia, C | 1 |
| Wegman-Ostrosky, T | 1 |
| Revilla-Vazquez, A | 1 |
| Jones, GR | 1 |
| Frohn, MJ | 1 |
| Beckett, AH | 1 |
| Fenton, BM | 1 |
| Nelson, JH | 1 |
| Winter, CC | 1 |
| Thomas, C | 1 |
| Counsell, C | 1 |
| Wood, P | 1 |
| Adams, GE | 1 |
| Okunieff, P | 1 |
| Kallinowski, F | 1 |
| Vaupel, P | 1 |
| Neuringer, LJ | 1 |
| Shimizu, H | 1 |
| Toth, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase 1b/2a Safety and Immunogenicity of the DNMT Inhibitor Azacitidine During Anti-Tuberculosis Therapy[NCT03941496] | Phase 1/Phase 2 | 0 participants (Actual) | Interventional | 2022-10-31 | Withdrawn (stopped due to The study was halted prematurely due to Bristol-Myers Squibb's (BMS) decision to withdraw support for this study.) | ||
| "Phase III Clinical Trial: Evaluation of the Combination of TRANSKRIP ® Plus Carboplatin and Paclitaxel as First Line Chemotherapy on Survival of Patients With Recurrent - Persistent Cervical Cancer"[NCT02446652] | Phase 3 | 230 participants (Anticipated) | Interventional | 2015-07-31 | Not yet recruiting | ||
| A Phase II Study of Epigenetic Therapy With Hydralazine and Magnesium Valproate to Overcome Chemotherapy Resistance in Refractory Solid Tumors[NCT00404508] | Phase 2 | 15 participants | Interventional | 2005-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for hydralazine and Benign Neoplasms
| Article | Year |
|---|---|
Hydralazine-valproate: a repositioned drug combination for the epigenetic therapy of cancer.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; DNA | 2014 |
Clinical and biological effects of demethylating agents on solid tumours - A systematic review.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cytidine; Decitabine; DNA Methylation; Humans; Hydrala | 2017 |
2 trials available for hydralazine and Benign Neoplasms
| Article | Year |
|---|---|
Pharmacokinetics of hydralazine, an antihypertensive and DNA-demethylating agent, using controlled-release formulations designed for use in dosing schedules based on the acetylator phenotype.
Topics: Acetylation; Administration, Oral; Adolescent; Adult; Antihypertensive Agents; Case-Control Studies; | 2011 |
A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; DNA Methylation; Drug Resistance, Neopla | 2007 |
A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; DNA Methylation; Drug Resistance, Neopla | 2007 |
A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; DNA Methylation; Drug Resistance, Neopla | 2007 |
A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; DNA Methylation; Drug Resistance, Neopla | 2007 |
12 other studies available for hydralazine and Benign Neoplasms
| Article | Year |
|---|---|
A Nanoplatform to Amplify Apoptosis-to-Pyroptosis Immunotherapy via Immunomodulation of Myeloid-Derived Suppressor Cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Drug Carriers; Drug Liberation; Female; | 2021 |
Upregulation of NKG2D ligands and enhanced natural killer cell cytotoxicity by hydralazine and valproate.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cytotoxicity, Immunologic; Histocompatibility Antigens Clas | 2011 |
Impact of tumor blood flow modulation on tumor sensitivity to the bioreductive drug banoxantrone.
Topics: Angiogenesis Inhibitors; Animals; Anthraquinones; Antineoplastic Agents; Axitinib; Cell Hypoxia; Cel | 2013 |
[Tests in the treatment of cancer. Preliminary note].
Topics: Desoxycorticosterone; Hydralazine; Neoplasms | 1961 |
CARCINOMA AND HYDRALAZINE TOXICITY IN PATIENTS WITH MALIGNANT HYPERTENSION.
Topics: Breast Neoplasms; Carcinoma; Humans; Hydralazine; Hypertension; Hypertension, Malignant; Lung Neopla | 1963 |
In vivo determination of tumor oxygenation during growth and in response to carbogen breathing using 15C5-loaded alginate capsules as fluorine-19 magnetic resonance imaging oxygen sensors.
Topics: Alginates; Animals; Carbon Dioxide; Cell Hypoxia; Crown Ethers; Fluorine; Glucuronic Acid; Hexuronic | 2004 |
Liminal therapy: a strategy for the complete and selective destruction of malignant tissue in situ.
Topics: Animals; Antineoplastic Agents; Cell Survival; Dihydralazine; Drug Resistance; Energy Metabolism; Hu | 1984 |
Influence of hydralazine administration on oxygenation in spontaneous and transplanted tumor models.
Topics: Animals; Carbocyanines; Cell Hypoxia; Etanidazole; Female; Fibrosarcoma; Fluorescent Dyes; Hydralazi | 2001 |
Priapism: evolution of management in 48 patients in a 22-year series.
Topics: Adolescent; Adult; Aged; Anemia, Sickle Cell; Anticoagulants; Antipsychotic Agents; Child; Child, Pr | 1977 |
Use of fluorine-19 nuclear magnetic resonance spectroscopy and hydralazine for measuring dynamic changes in blood perfusion volume in tumors in mice.
Topics: Animals; Carcinoma, Squamous Cell; Fluorine; Fluorocarbons; Hydralazine; Hydrocarbons, Brominated; M | 1992 |
Effects of hydralazine-induced vasodilation on the energy metabolism of murine tumors studied by in vivo 31P-nuclear magnetic resonance spectroscopy.
Topics: Animals; Blood Pressure; Cardiac Output; Dose-Response Relationship, Drug; Energy Metabolism; Female | 1988 |
Species dependent toxicity of six substituted hydrazines.
Topics: Allyl Compounds; Animals; Benzoates; Benzyl Compounds; Cricetinae; Dose-Response Relationship, Drug; | 1974 |